All Stories

  1. Reproductive dysfunction in hemodialysis: endocrine mechanisms, clinical features, and therapeutic approaches
  2. Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series
  3. Unraveling the Genetic Links Between Polycystic Kidney Disease and Hypertension Through ARL13B
  4. The impact of hemodiafiltration with endogenous reinfusion (HFR) on micronutrient status in patients undergoing maintenance hemodialysis: A randomized crossover trial
  5. Protein lactylation in kidney diseases
  6. Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence
  7. Efficacy and safety of TRF-budesonide in IgA nephropathy treatment: a meta-analysis
  8. The Influence of Different Kidney Replacement Modalities on Health-Related Quality of Life in ESKD Patients
  9. Alterations of renal polyamine metabolism in mice with folic acid-induced chronic kidney disease
  10. Assessment of thiamine status and its association with clinical parameters in patients undergoing maintenance hemodialysis
  11. Peridialytic Erythropoietin versus Roxadustat in Hemodialysis-dependent CKD Patients
  12. Sarcopenia in Peritoneal Dialysis: Prevalence, Pathophysiology, and Management Strategies
  13. Precision Treatment of IgA Nephropathy Based on a New Framework: Angiorenal Protection, Immunity Inhibition, B-Cell/Plasma-Cell Modulation, and Complement Inhibition
  14. Antinephrin autoantibodies: rethinking the pathogenesis of minimal change disease
  15. Monocyte/macrophage pyroptosis and C5b-9-induced cyst enlargement in Pkd1−/− mice
  16. COVID-19-Associated Immune Thrombocytopenic Purpura in a Hemodialysis Patient
  17. Integrated mRNA-seq and miRNA-seq analysis reveals key transcription factors of HNF4α and KLF4 in ADPKD
  18. EZH2 inhibition or genetic ablation suppresses cyst growth in autosomal dominant polycystic kidney disease
  19. Prognostic Assessment of Histopathologic Lesions in Patients with Community-Acquired AKI with Biopsy-Proven Acute Tubular Necrosis
  20. Deciphering interleukin 37's therapeutic potential: insights into alleviating inflammation in autosomal dominant polycystic kidney disease
  21. Obstructive uropathy complicated by acute aortic dissection
  22. Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report
  23. A pilot study of intensive short‐time continuous renal replacement therapy to substitute maintenance hemodialysis during transitional period of COVID‐19
  24. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
  25. Potential factors associated with a long-term duration of B-cell depletion after using rituximab in patients with nephrotic syndrome
  26. Misdiagnosis of renal pelvic unicentric Castleman disease: a case report
  27. Specific Nutritional Strategy Is Needed for Good Nutritional Status in Autosomal Dominant Polycystic Kidney Disease
  28. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD
  29. Golden mean of serum uric acid level on the risk of kidney function decline
  30. Vascular calcification on the risk of kidney stone: a meta-analysis
  31. Automatic Segmentation of Kidney Volume Using Multi-Module Hybrid Based U-Shape in Polycystic Kidney Disease
  32. Urine biomarkers can outperform serum biomarkers in certain diseases
  33. A Nomogram to Identify Hyperkalemia Risk in Patients with Advanced CKD
  34. p-Cresyl sulfate predicts clinical outcomes in sustained peritoneal dialysis: a 5-year follow-up cohort study and meta-analysis
  35. Susceptibility of renal fibrosis in diabetes: Role of hypoxia inducible factor‐1
  36. Anoctamin 1 Inhibition Suppresses Cystogenesis by Enhancing Ciliogenesis and the Ciliary Dosage of Polycystins
  37. Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease
  38. In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study
  39. Late venous laceration after inappropriate placement of a left internal jugular hemodialysis catheter: a case report
  40. A program for early detection and management of chronic kidney disease
  41. Prognostic analysis of crescentic glomerulonephritis with acute kidney injury: a single-center cohort with 5-year follow-up
  42. Comparison of Outcomes between Percutaneous and Surgical Placement of Peritoneal Dialysis Catheters in Uremic Patients: A Meta-Analysis
  43. Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression
  44. The Role of Renal Pathology in the Prognosis and Recovery of Community-Acquired Acute Kidney Injury
  45. Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia
  46. Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review
  47. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis
  48. Inflammatory cytokines depletion for severe COVID-19 infectious pneumonia: a case report
  49. The fertility willingness and acceptability of preimplantation genetic testing in Chinese patients with autosomal dominant polycystic kidney disease
  50. Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China
  51. Effect of Statins on Renal Function and Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
  52. COVID-19 Infection in a Patient with End-Stage Kidney Disease
  53. Nocturnal Hemodialysis Compared with Conventional Dialysis for End-Stage Renal Disease Treatment in Polycystic Kidney Disease Patients
  54. Treatment Options for Kidney Failure in China: Conservative Management More Than Dialysis?
  55. New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review
  56. Timing of Renal-Replacement Therapy in Acute Kidney Injury and Sepsis
  57. Is urinary oxalate inversely correlated with glomerular filtration rate in chronic kidney disease?
  58. Identification of Key Genes and Candidated Pathways in Human Autosomal Dominant Polycystic Kidney Disease by Bioinformatics Analysis
  59. Clinical Characteristics and Outcomes of Community-Acquired versus Hospital-Acquired Acute Kidney Injury: A Meta-Analysis
  60. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials
  61. Polycystic Kidney Disease and Renal Fibrosis
  62. Changing procedures for resolving medical disputes in China
  63. Preimplantation Genetic Diagnosis of Autosomal Dominant Polycystic Kidney Disease Applied in China
  64. Fibroblast Growth Factor-23 May Follow Cardiovascular Disease Rather than Causing It in Chronic Kidney Disease
  65. Dialysis modality and mortality in polycystic kidney disease
  66. Saikosaponin-d inhibits proliferation by up-regulating autophagy via the CaMKKβ–AMPK–mTOR pathway in ADPKD cells
  67. Total kidney volume: the most valuable predictor of autosomal dominant polycystic kidney disease progression
  68. Comment to: Differences in characteristics and outcomes between community- and hospital-acquired acute kidney injury: A systematic review and meta-analysis. Clinical Nephrology, 2017; 88: 167-182
  69. Amputation of the first metatarsophalangeal joint due to a giant gouty tophi
  70. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial
  71. Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease
  72. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China
  73. Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials
  74. Relationship of pre-operative serum brain natriuretic peptide with risk of acute kidney injury after cardiac surgery
  75. Effects ofendothelial nitric oxide synthasegene on end stage renal disease progression in autosomal dominant polycystic kidney disease
  76. 4 G/4 G polymorphism ofplasminogen activator inhibitor-1 geneincreases the risk of diabetic nephropathy
  77. Apolipoprotein E Gene Variants on the Risk of End Stage Renal Disease
  78. C509T and T869C polymorphisms of transforming growth factor β1 and the risk of IgA nephropathy: a meta-analysis
  79. Chronic kidney disease-mineral and bone disorder and energy metabolism
  80. Secretoglobin 1A member 1 (SCGB1A1) +38A/G polymorphism is associated with asthma risk: A meta-analysis
  81. Long-Term Treatment with Mammalian Target of Rapamycin Inhibitor Does Not Benefit Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-Analysis
  82. Histone deacetylases and autosomal dominant polycystic kidney disease